What patients with primary ITP prefer in their treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses a preference elicitation survey to understand what patients with primary ITP value when choosing treatments. The project has two stages: developing the survey and then administering the finalized survey to collect data, followed by analysis of patient preferences. Data collection will occur in the United States with adults who have an ITP diagnosis and are at either first-line or second-line treatment stages. The study is non-interventional and does not involve testing new therapies.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Currently living in the US.
2. Aged 18 years and older on the day of providing informed consent.
3. A diagnosis of primary ITP:

   a. For participants receiving first-line (1L) treatment for ITP: i. Diagnosed with primary ITP and started 1L corticosteroids within 3 months of diagnosis ii. Responded to 1L corticosteroid treatment \[with or without intravenous immunoglobulin (IVIg)\] b. For participants receiving second-line (2L) treatment for ITP: i. Assessed as needing or are taking thrombopoietin receptor agonist (TPO-RA) treatment for 2L treatment ii. Has previously been treated with a 1L corticosteroid (with or without IVIg) with insufficient response or relapse

Exclusion criteria:

1. For participants receiving 1L treatment for ITP only: Previous or current use of treatments different from corticosteroids and/or IVIg/anti-D immunoglobulin.
2. For participants receiving 2L ITP treatment: Previous or current use of treatments different from corticosteroids, IVIg/anti-D immunoglobulin or one TPO-RA (i.e. patients who have used any treatment in a third-line setting are ineligible).

Where it's running

• Novartis
  East Hanover, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SG301 SC Injection safety in adults with primary ITP

  This Phase 2 study tests SG301 SC injection at two doses versus placebo in adults with primary immune thrombocytopenia to see if it is safe and helps raise platelet counts.

  Recruiting at 14 sites Phase 2 Hangzhou Sumgen Biotech Co., Ltd. · Fuzhou, Fujian and 21 other locations · NCT07710248

• Romiplostim plus prednisone vs prednisone alone in adults with newly diagnosed ITP

  This phase 3 trial tests whether adding romiplostim to prednisone helps adults with newly diagnosed primary ITP respond better than prednisone alone.

  Recruiting at 3 sites Phase 3 Amgen · Long Beach, California and 2 other locations · NCT07700238

• TQB3473 tablets for treating adult primary immune thrombocytopenia

  This study is testing if TQB3473 tablets can help adults with chronic immune thrombocytopenia who haven't responded well to standard treatments feel better and have more stable blood platelet levels.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 52 other locations · NCT06900920

• Using Eltrombopag as a first treatment for Primary Immune Thrombocytopenia

  This study is testing if a new medication called eltrombopag can help people who are newly diagnosed with Primary Immune Thrombocytopenia by increasing their platelet counts and reducing bleeding.

  Recruiting Phase 1/2 Renata PLC · Dhaka · NCT06531018

• Long-term observation of children with primary immune thrombocytopenia

  This study looks at how children with primary immune thrombocytopenia are treated and what their long-term health outcomes are in order to better understand the condition.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06107582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.